COPD

Dupilumab in patients with uncontrolled COPD reduced annual exacerbations by 30%, a statistically significant and clinically meaningful outcome and a first for a biologic.

Your daily dose of clinical news you may have missed.

The CAPTURE tool was able to identify 50% of primary care patients with COPD who could immediately benefit from treatment; experts say, it's a start.

Your daily dose of clinical news you may have missed.

Among patients with COPD and OSA, those with consistent CPAP compliance over 12 months showed improved lung function and experienced fewer AECOPD.

Prediction of COPD exacerbations was significantly better with a CT biomarker-based model than either exacerbation history or BODE index.

COPD was associated with a 61% increase in risk of death and 13% greater total costs in the year after surgery, according to a new study.

Exacerbation history alone is unlikely to provide clinical utility for predicting future COPD exacerbations and could be associated with a risk of harm, according to new analysis.

Your daily dose of clinical news you may have missed.

CHEST. After a moderate COPD event, treatment with TT within 30 days significantly reduced risk for exacerbation over 12 months vs treatment after 30 days.

In-hospital pulmonary rehabilitation improves function and symptoms in COPD patients whether they are on triple therapy or not, a new study confirms.

Findings highlight the need for more real-life studies to support decision making within primary care settings, say researchers.

Lung airways were smaller in women than men, even among ever-smokers and never-smokers, according to large analysis.

Additional research into tailored metered-dose inhaler education is needed, according to authors of a recent study.

When asthma and COPD patients have a continuous relationship with a single provider, ED visits/hospitalizations go down, survival goes up, finds a new systematic review.

In persons with COPD, seasonal influenza and PPSV23 vaccines, separately or together, reduced the risk for COPD- and pneumonia-related hospitalizations.

Authors of this first study to compare the combinations head-to-head suggest that the glycopyrrolate combination is appropriate for long-term COPD management.

Asthma-COPD overlap and obesity mutually exacerbate each other and an early program of pulmonary rehabilitation shows promise to help both.

The FDA has approved the first generic budesonide and formoterol fumarate dihydrate inhalation aerosol for the treatment of asthma and COPD.

AAAAI late-breaking science and findings that could change your treatment plan for patients with severe asthma, summarized by our editors for easy access.

New study findings on asthma exacerbation risk prediction, rapid steroid reduction, and patient perception of disease lead this quick quiz.

Research summaries on GINA revisions, a steroid-reduction algorithm, factors that predict asthma exacerbation risk, and more.

New research highlights several key risk factors that are likely to accelerate the progression from asthma to COPD, including older age and prior tobacco use.

Occupational exposure to pesticides was linked to an increased risk of COPD in a large UK study.

The Guideline Toplines slide-show feature offers busy primary care physicians at-a-glance summaries of new and updated clinical guidelines across therapeutic areas.

CHEST 2021: Study shows vaping raises the odds of developing asthma and COPD, especially in older adults, women, and Hispanic persons.

A new study found public health measures designed to curb COVID-19 transmissions may have fostered a significant side benefit: reduced COPD hospital admissions.

ATS 2021: The risk of morbidity and death in patients with COPD increases among those with moderate exacerbation, and even more so for severe exacerbation, new research suggests.

In an abstract being presenting at the upcoming ATS 2021 International Conference, researchers estimate that by 2050 the US will lead the Americas in prevalence of COPD.

American Thoracic Society 2021 International Conference: In a subset of patients from the ETHOS study, triple combination therapy was found beneficial for those with moderate COPD.